| http://dbpedia.org/ontology/abstract
|
Il CERA (acronimo di Continuous Erythropoi … Il CERA (acronimo di Continuous Erythropoietin Receptor Activator, "attivatore continuo del recettore dell'eritropoietina") è un farmaco utilizzato dal 2007 sui pazienti con insufficienza renale e costretti all'emodialisi. Dal 2008 è assurto agli onori delle cronache sportive perché utilizzato da alcuni ciclisti come doping. Inizialmente difficile da trovarsi nelle analisi, è anche conosciuto come EPO di terza generazione (ove la Dynepo è quella di seconda). MIRCERAve la Dynepo è quella di seconda). MIRCERA
, La CERA (siglas en inglés de Continuous er … La CERA (siglas en inglés de Continuous erythropoietin receptor activator Activador continuo del receptor de la eritropoyetina) es el término genérico con el que se conocen los fármacos que son ESA (agentes estimuladores de eritropoyesis) de tercera generación. Los efectos de la CERA duran más que las ESAs de generaciones anteriores, y su mecanismo de funcionamiento es también distinto: la CERA estimula el receptor de la eritropoyetina (EPO), aumentando los efectos de la EPO, es decir, estimulando la hematopoyesis.O, es decir, estimulando la hematopoyesis.
, Cera (merknaam: Mircera) is een derde gene … Cera (merknaam: Mircera) is een derde generatie epo. Het is de afkorting van "continuous erythropoiesis receptor activator". Het kwam in 2007 op de markt en wordt geproduceerd door Hoffmann-La Roche. Het is zoals alle andere vormen van erytropoëtine een hormoon, in dit geval kunstmatig gemaakt, dat normaliter door de nier wordt aangemaakt en dat de vorming van rode bloedcellen in het lichaam stimuleert. Het middel wordt gebruikt als geneesmiddel bij bloedarmoede of ter voorkoming van bloedarmoede bij kankerpatiënten tijdens de chemokuur. Doel van het ontwikkelen van deze derde generatie erytropoëtine was dat het middel slechts om de drie tot vier weken toegediend hoeft te worden. De volledige naam van dit product is methoxypolyethyleenglycol-epoëtine beta.s methoxypolyethyleenglycol-epoëtine beta.
, La CERA (sigles en anglès de Continuous er … La CERA (sigles en anglès de Continuous erythropoietin receptor activator Activador continu del receptor de l'eritropoietina) és el terme genèric amb què es coneixen els fàrmacs que són (agents estimuladors d'eritropoesi) de tercera generació. Els efectes de la CERA duren més que les ESAs de generacions anteriors, i el seu mecanisme de funcionament també és diferent: la CERA estimula el receptor de l'eritropoetina (EPO), augmentant els efectes de l'EPO, és a dir, estimulant l'hematopoesi.l'EPO, és a dir, estimulant l'hematopoesi.
, 持続性エリスロポエチン受容体活性化剤（じぞくせいエリスロポエチンじゅようたいかっせいかざい）とは、エフ・ホフマン・ラ・ロシュ社が開発した貧血治験薬のこと。英語では、Continuous Erythropoietin Receptor Activatorと表記されることから、その頭文字を取って、一般的にCERAという略称が用いられている。
, Continuous erythropoietin receptor activat … Continuous erythropoietin receptor activator (CERA) is the generic term for drugs in a new class of third-generation erythropoiesis-stimulating agents (ESAs). In the media, these agents are commonly referred to as 'EPO', short for erythropoietin. CERAs have an extended half-life and a mechanism of action that promotes increased stimulation of erythropoietin receptors compared with other ESAs. Under the trade name Mircera, Roche Pharmaceuticals received approval from the U.S. Food and Drug Administration (FDA) in January 2008 to market a continuous erythropoiesis receptor activator (methoxy polyethylene glycol-epoetin beta) for the treatment of anemia in patients with chronic kidney disease, including in those undergoing dialysis. This issue appears to have been resolved since Fresenius Medical dialysis clinics in the US are now administering this drug.) Methoxy polyethylene glycol-epoetin beta had been approved by the European Commission in August 2007, and was made available in Europe at the start of 2008. In terms of its structure, Mircera is similar to the previous synthetic EPO drugs, except that it is connected to a chemical called polyethylene glycol (PEG), which makes it last longer in the body. According to Roche, the product has the longest half-life of all FDA-approved erythropoiesis-stimulating agents (ESAs): up to 6 times longer than darbepoetin alfa and up to 20 times longer than epoetin. CERAs thus promise both lower dosing—significant owing to the high inherent cost of manufacturing recombinant protein drugs—and less frequent injections for patients. ESAs are administered via subcutaneous injections, often in doctor's offices for patients who lack the skill or dexterity to inject themselves, so the once- or twice-monthly dosing regimen for CERAs promises fewer costly, inconvenient office visits for patients requiring constant hemoglobin level maintenance for chronic kidney disease. In clinical trials, CERA dosed every 3 to 4 weeks demonstrated efficacy similar to that of epoetin alfa and darbepoetin alfa in maintaining hemoglobin concentrations within the target hemoglobin range. CERA has generally been well tolerated in clinical trials.ly been well tolerated in clinical trials.
|
| http://dbpedia.org/ontology/wikiPageID
|
18486827
|
| http://dbpedia.org/ontology/wikiPageLength
|
8419
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1102170137
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/NGO +
, http://dbpedia.org/resource/Don_Catlin +
, http://dbpedia.org/resource/Union_Cycliste_Internationale +
, http://dbpedia.org/resource/2008_Olympic_Games +
, http://dbpedia.org/resource/Bernhard_Kohl +
, http://dbpedia.org/resource/Erythropoiesis-stimulating_agent +
, http://dbpedia.org/resource/Davide_Rebellin +
, http://dbpedia.org/resource/Riccardo_Ricco +
, http://dbpedia.org/resource/Leonardo_Piepoli +
, http://dbpedia.org/resource/Stefan_Schumacher +
, http://dbpedia.org/resource/Food_and_Drug_Administration +
, http://dbpedia.org/resource/Equine_test +
, http://dbpedia.org/resource/Methoxy_polyethylene_glycol-epoetin_beta +
, http://dbpedia.org/resource/Giro_d%27Italia +
, http://dbpedia.org/resource/Rashid_Ramzi +
, http://dbpedia.org/resource/Erik_Tysse +
, http://dbpedia.org/resource/IAAF +
, http://dbpedia.org/resource/Anemia +
, http://dbpedia.org/resource/Category:Erythropoiesis-stimulating_agents +
, http://dbpedia.org/resource/Chronic_kidney_disease +
, http://dbpedia.org/resource/Polyethylene_glycol +
, http://dbpedia.org/resource/Polka-dot_jersey +
, http://dbpedia.org/resource/Hemoglobin +
, http://dbpedia.org/resource/European_Commission +
, http://dbpedia.org/resource/Mircera +
, http://dbpedia.org/resource/Use_of_performance-enhancing_drugs_in_sport +
, http://dbpedia.org/resource/2008_Tour_de_France +
, http://dbpedia.org/resource/Erythropoietin +
, http://dbpedia.org/resource/International_Olympic_Committee +
, http://dbpedia.org/resource/Danilo_Di_Luca +
, http://dbpedia.org/resource/Kidney_dialysis +
, http://dbpedia.org/resource/Roche_Pharmaceuticals +
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Cite_journal +
, http://dbpedia.org/resource/Template:By_whom +
, http://dbpedia.org/resource/Template:More_citations_needed +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Citation_needed +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Erythropoiesis-stimulating_agents +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Term +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Continuous_erythropoietin_receptor_activator?oldid=1102170137&ns=0 +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Continuous_erythropoietin_receptor_activator +
|
| owl:sameAs |
http://ja.dbpedia.org/resource/%E6%8C%81%E7%B6%9A%E6%80%A7%E3%82%A8%E3%83%AA%E3%82%B9%E3%83%AD%E3%83%9D%E3%82%A8%E3%83%81%E3%83%B3%E5%8F%97%E5%AE%B9%E4%BD%93%E6%B4%BB%E6%80%A7%E5%8C%96%E5%89%A4 +
, https://global.dbpedia.org/id/2haDC +
, http://nl.dbpedia.org/resource/Cera_%28epovariant%29 +
, http://he.dbpedia.org/resource/CERA +
, http://rdf.freebase.com/ns/m.04f0mdq +
, http://www.wikidata.org/entity/Q2914445 +
, http://es.dbpedia.org/resource/CERA_%28f%C3%A1rmaco%29 +
, http://fi.dbpedia.org/resource/Cera +
, http://dbpedia.org/resource/Continuous_erythropoietin_receptor_activator +
, http://ca.dbpedia.org/resource/CERA_%28f%C3%A0rmac%29 +
, http://da.dbpedia.org/resource/CERA +
, http://yago-knowledge.org/resource/Continuous_erythropoietin_receptor_activator +
, http://it.dbpedia.org/resource/CERA +
, http://no.dbpedia.org/resource/Continuous_erythropoietin_receptor_activator +
|
| rdf:type |
http://dbpedia.org/class/yago/WikicatHormones +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
, http://dbpedia.org/class/yago/BodySubstance105263850 +
, http://dbpedia.org/class/yago/Secretion105404728 +
, http://dbpedia.org/class/yago/WikicatProteins +
, http://dbpedia.org/class/yago/Hormone105407119 +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://dbpedia.org/class/yago/LiquidBodySubstance105397468 +
, http://dbpedia.org/class/yago/Protein114728724 +
, http://dbpedia.org/class/yago/OrganicCompound114727670 +
, http://dbpedia.org/class/yago/Abstraction100002137 +
, http://dbpedia.org/class/yago/Material114580897 +
, http://dbpedia.org/class/yago/Macromolecule114944888 +
, http://dbpedia.org/class/yago/Molecule114682133 +
, http://dbpedia.org/class/yago/Unit109465459 +
, http://dbpedia.org/class/yago/Compound114818238 +
, http://dbpedia.org/class/yago/Chemical114806838 +
, http://dbpedia.org/class/yago/Substance100019613 +
, http://dbpedia.org/class/yago/Part113809207 +
, http://dbpedia.org/class/yago/Thing100002452 +
, http://dbpedia.org/class/yago/Relation100031921 +
|
| rdfs:comment |
Cera (merknaam: Mircera) is een derde gene … Cera (merknaam: Mircera) is een derde generatie epo. Het is de afkorting van "continuous erythropoiesis receptor activator". Het kwam in 2007 op de markt en wordt geproduceerd door Hoffmann-La Roche. Het is zoals alle andere vormen van erytropoëtine een hormoon, in dit geval kunstmatig gemaakt, dat normaliter door de nier wordt aangemaakt en dat de vorming van rode bloedcellen in het lichaam stimuleert. Het middel wordt gebruikt als geneesmiddel bij bloedarmoede of ter voorkoming van bloedarmoede bij kankerpatiënten tijdens de chemokuur. Doel van het ontwikkelen van deze derde generatie erytropoëtine was dat het middel slechts om de drie tot vier weken toegediend hoeft te worden. De volledige naam van dit product is methoxypolyethyleenglycol-epoëtine beta.s methoxypolyethyleenglycol-epoëtine beta.
, Il CERA (acronimo di Continuous Erythropoi … Il CERA (acronimo di Continuous Erythropoietin Receptor Activator, "attivatore continuo del recettore dell'eritropoietina") è un farmaco utilizzato dal 2007 sui pazienti con insufficienza renale e costretti all'emodialisi. Dal 2008 è assurto agli onori delle cronache sportive perché utilizzato da alcuni ciclisti come doping. Inizialmente difficile da trovarsi nelle analisi, è anche conosciuto come EPO di terza generazione (ove la Dynepo è quella di seconda). MIRCERAve la Dynepo è quella di seconda). MIRCERA
, La CERA (siglas en inglés de Continuous er … La CERA (siglas en inglés de Continuous erythropoietin receptor activator Activador continuo del receptor de la eritropoyetina) es el término genérico con el que se conocen los fármacos que son ESA (agentes estimuladores de eritropoyesis) de tercera generación. Los efectos de la CERA duran más que las ESAs de generaciones anteriores, y su mecanismo de funcionamiento es también distinto: la CERA estimula el receptor de la eritropoyetina (EPO), aumentando los efectos de la EPO, es decir, estimulando la hematopoyesis.O, es decir, estimulando la hematopoyesis.
, 持続性エリスロポエチン受容体活性化剤（じぞくせいエリスロポエチンじゅようたいかっせいかざい）とは、エフ・ホフマン・ラ・ロシュ社が開発した貧血治験薬のこと。英語では、Continuous Erythropoietin Receptor Activatorと表記されることから、その頭文字を取って、一般的にCERAという略称が用いられている。
, Continuous erythropoietin receptor activat … Continuous erythropoietin receptor activator (CERA) is the generic term for drugs in a new class of third-generation erythropoiesis-stimulating agents (ESAs). In the media, these agents are commonly referred to as 'EPO', short for erythropoietin. CERAs have an extended half-life and a mechanism of action that promotes increased stimulation of erythropoietin receptors compared with other ESAs.oietin receptors compared with other ESAs.
|
| rdfs:label |
持続性エリスロポエチン受容体活性化剤
, CERA (fármaco)
, Cera (epovariant)
, CERA
, CERA (fàrmac)
, Continuous erythropoietin receptor activator
|
